Solid organ transplantation after hematopoietic stem cell transplantation in childhood : A multicentric retrospective survey
Faraci, Maura (Istituto G Gaslini)
Bertaina, Alice (Stanford University)
Dalissier, Arnaud (European Society for Blood and Marrow Transplantation Pediatric Disease Working Party)
Ifversen, Marianne (Copenhagen University Hospital)
Schulz, Ansgar (University Medical Center)
Gennery, Andrew (Great North Children's Hospital)
Burkhardt, Birgit (University Hospital of Münster (Alemanya))
Badell Serra, Isabel (Institut d'Investigació Biomèdica Sant Pau)
Díaz de Heredia, Cristina (Vall d'Hebron Institut d'Oncologia)
Lanino, Edoardo (Istituto G Gaslini)
Lankester, Arjan C. (Leiden University Medical Center)
Gruhn, Bernd (Jena University Hospital (Alemania))
Matthes-Martin, Susanne Medical University of Vienna
Kühl, Joern S. (Universitätsklinikum Leipzig)
Varotto, Stefania (University Hospital of Padova (Pàdua, Itàlia))
Paillard, Catherine (Hôpital Hautepierre)
Guilmatre, Audrey (Hôpital Armand Trousseau (París, França))
Sastre, Ana (Hospital Universitario La Paz (Madrid))
Abecasis, Manuel (Instute Portugues Oncologia Lisboa)
Garwer, Birgit (University Hospital Eppendorf)
Sedlacek, Petr (University Hospital Motol)
Boelens, Jaap Jan (Memorial Sloan Kettering Cancer Center)
Beohou, Eric (European Society for Blood and Marrow Transplantation Pediatric Disease Working Party)
Bader, Peter (University Hospital of Frankfurt (Alemanya))
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	We report data obtained from a retrospective multicenter pediatric survey on behalf of the European Society for Blood and Marrow Transplantation (EBMT). Information on solid organ transplantation (SOT) performed in pediatric recipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 was collected in 20 pediatric EBMT Centers (25. 6%). Overall, we evaluated data on 44 SOTs following HSCT including 20 liver (LTx), 12 lung (LuTx), 6 heart (HTx), and 6 kidney (KTx) transplantations. The indication for SOT was organ failure related to intractable graft-vs-host disease in 16 children (36. 3%), acute or chronic HSCT-related toxicity in 18 (40. 9%), and organ dysfunction related to the underlying disease in 10 (22. 8%). The median follow-up was 10. 9 years (95% confidence interval: 1. 7-29. 5). The overall survival rate at 1 and 5 years after SOT was 85. 7% and 80. 4%, respectively: it was 74% and 63. 2% after LTx, 83. 2% after HTx, and 100% equally after LuTx and KTx. This multicenter survey confirms that SOT represents a promising option in children with severe organ failure occurring after HSCT. Additional studies are needed to further establish the effectiveness of SOT after HSCT and to better understand the mechanism underlying this encouraging success.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Bone marrow/hematopoietic stem cell transplantation ; Clinical research/practice ; Graft-vs-host disease (GVHD) ; Heart failure/injury ; Kidney failure/injury ; Liver disease ; Lung (allograft) ; Function/dysfunction ; Organ transplantation in general ; Pediatrics
Publicado en:	American Journal of Transplantation, Vol. 19 Núm. 6 (june 2019) , p. 1798-1805, ISSN 1600-6143

DOI: 10.1111/ajt.15240
PMID: 30586230

8 p, 316.8 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados